yahoo_financeOriginal article
Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study
RegulatoryErsodetugNeutral
AI Analysis
Summary
Rezolute announced that the FDA continues to review data from its Phase 3 congenital hyperinsulinism study for ersodetug. No decision outcome or expected timeline was provided in the brief announcement.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA review ongoing
Importance:4/10
Sentiment:
0.00
FDA reviewPhase 3Congenital Hyperinsulinismregulatory update
Related Companies
Read the original article
Published by yahoo_finance on September 9, 2026 12:30 PM